CITIZENS NEWS

FDA turns blind eye to 70,000 adverse events from puberty blockers, prioritizing politics over child safety

By isabelle // 2025-02-26

• The FDA has ignored over 70,000 adverse event reports tied to puberty-blocking drugs, despite severe risks like heart attacks, blood clots, and psychological harm.
• Puberty blockers are now widely prescribed off-label for minors, despite evidence of irreversible harm.
• Studies link puberty blockers to increased risks of stroke, bone density loss, cognitive decline, and psychological distress, with nearly 100% of users progressing to cross-sex hormones.
• The FDA’s inaction contrasts sharply with its swift warnings on drugs like ivermectin, raising concerns about political influence over child safety.
• The UK’s NHS has banned routine use of puberty blockers, citing safety concerns, while the FDA remains silent, leaving American children at risk.

The U.S. Food and Drug Administration (FDA) has failed to address over 70,000 adverse event reports linked to puberty-blocking drugs, despite mounting evidence of their severe health risks. These drugs, often prescribed off-label for gender transitions in minors, have been tied to life-threatening conditions such as heart attacks, blood clots, and psychological harm. While the UK’s National Health Service (NHS) has banned their routine use due to safety concerns, the FDA has remained silent, raising questions about its commitment to protecting children over political agendas. The FDA’s inaction stands in alarming contrast to its aggressive warnings against the off-label use of drugs like ivermectin and hydroxychloroquine, which have far fewer reported adverse events but were touted by conservatives. Critics argue that the agency’s priorities are skewed, leaving vulnerable children exposed to irreversible harm due to political concerns.

Puberty blockers are a dangerous experiment on children

Puberty blockers, such as Lupron, were originally approved by the FDA to treat prostate cancer and precocious puberty. However, they are now widely prescribed off-label to halt natural puberty in children questioning their gender. These drugs suppress the production of sex hormones, effectively freezing physical development. While proponents claim they are reversible, mounting evidence suggests otherwise. Studies have linked puberty blockers to a seven-fold increase in the risk of stroke, heart attack, and blood clots. Other reported side effects include severe bone density loss, cognitive decline, and psychological distress. In the UK, the NHS halted routine prescriptions of puberty blockers after a landmark review by Dr. Hilary Cass found insufficient evidence of their safety or efficacy. “The effects of puberty suppression on emotional and cognitive development are more difficult to ascertain, but more consequential as they could potentially affect the capacity to consent to cross-sex hormones and surgery,” wrote Dr. Michael Biggs in a recent study published in the Journal of Sex and Marital Therapy. Moreover, nearly 100% of children who start puberty blockers go on to take cross-sex hormones, raising concerns about the irreversible nature of these treatments.

FDA’s silence speaks volumes

Despite receiving 70,000 adverse event reports, the FDA’s Drug Risk Monitoring Board (DRMB) has not listed puberty blockers as a safety priority. This omission is particularly alarming given the agency’s history of swift action on other drugs. For example, the FDA launched a high-profile campaign against hydroxychloroquine after just 331 adverse event reports, many of which involved misuse. Dr. David Gortler, a former FDA senior advisor, criticized the agency’s lack of transparency. “The FDA knows exactly how to inform Americans about critical drug safety matters…if it wants to,” he said. “But for one reason or another, it isn’t.” The FDA’s reluctance to act may stem from political pressures. Under the Biden administration, puberty blockers for gender transitions were set to be covered by taxpayers, despite their high cost—up to $14,000 every six months for a single drug like Lupron. Meanwhile, the agency has prioritized politically motivated warnings, such as those against ivermectin, while ignoring the dangers of puberty blockers. The UK’s decision to ban puberty blockers outside of clinical trials has set a precedent for prioritizing evidence-based care. In contrast, the FDA’s inaction has left American children vulnerable to irreversible harm. One can only hope that under the FDA's new leadership, with Robert F. Kennedy Jr. as HHS Secretary, the agency will refocus on its mission to protect public health. “We have always been clear that children’s safety and wellbeing is paramount,” said UK Health Minister Maria Caulfield, welcoming the NHS’s decision. Similar clarity and courage are desperately needed in the U.S. As the debate over puberty blockers continues, the FDA’s failure to act on 70,000 adverse event reports is a dereliction of duty. Protecting children from irreversible harm should be the agency’s top priority—not political posturing.   Sources for this article include: Brownstone.org DailyMail.co.uk TheFederalist.com ThePostMillennial.com

toxins FDA transgender big government depopulation insanity Dangerous Medicine gender transitioning outrage puberty blockers badhealth badmedicine